From NuGOwiki
The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB
| Taxonomy Navigation Box; search by |
|
All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein |
| Dihydrouracil | |
|---|---|
 | |
| Chemical Name | 1,3-diazinane-2,4-dione |
| Chemical Formula | C4H6N2O2 |
| CAS Number | 504-07-4 |
| Chemical Information | HMDB00076 |
| Biochemical Taxonomy |
|
| Functional Taxonomy | Not Available |
| Nutritional Taxonomy | Not Available |
| Metabolic Pathways |
|
| Biofluid Location |
|
| Tissue Location |
|
| Normal Biofluid Concentrations |
|
| Normal Tissue Concentrations | Not Available |
| Diseases / Conditions Related to Nutrition |
|
| Other (Monogenic Disorders) | Not Available |
| Abnormal Biofluid Concentrations |
|
| Abnormal Tissue Concentrations | Not Available |
| Physiological Processes | Not Available |
| Authors: | |
| Affiliations: |
Contents |
Introduction
guidelines
An intermediate breakdown product of uracil. Dihydropyrimidine dehydrogenase catalyzes the reduction of uracil to 5, 6-dihydrouracil then dihydropyrimidinase hydrolyzes 5, 6-dihydrouracil to N-carbamyl-b-alanine. Finally, beta-ureidopropionase catalyzes the conversion of N-carbamyl-b-alanine to beta-alanine. Patients with dihydropyrimidinase deficiency (DPYS; also called 5, 6-dihydropyrimidine amidohydrolase, or DHP; EC 3.5.2.2) exhibit highly increased concentrations of 5, 6-dihydrouracil in urine. The direct measurement of the activity of DHP in patients had been hampered by the fact that the enzyme is expressed almost exclusively in liver tissue. Various neurological abnormalities have been described in this group of patients. (OMIM 222748)
Biological Function
Catabolism
Diseases / Conditions Related to Nutrition
- Dihydropyrimidine dehydrogenase (DPD) deficiency
Other (Monogenic) Disorders